You are running an unsupported browser, please upgrade your browser. Close

Email Subscription

Stay in touch – sign up to receive all our latest news and updates.

Stay in touch – sign up to receive all our latest news and updates.

Biopharmaceuticals

Continuous Processing

Enhanced Performance from Start to Finish.

Continuous Processing Solutions

Pall has turned continuous bioprocessing theory into reality. Only Pall has the Continuous Ready products and integration expertise that has made Continuous Bioprocessing a reality. It enables bioprocessors to achieve the highest product quality, productivity and patient benefit with a dramatically smaller footprint and shorter lead times.    

Literature Library

  • What Are The Applications Of Continuous Processing?

    Enter your details to download

    Country
    • Afghanistan
    • Albania
    • Algeria
    • American Samoa
    • Andorra
    • Angola
    • Anguilla
    • Antarctica
    • Antigua and Barbuda
    • Argentina
    • Aruba
    • Australia
    • Austria
    • Bahamas
    • Bahrain
    • Bangladesh
    • Barbados
    • Belgium
    • Belize
    • Benin
    • Bermuda
    • Bhutan
    • Bolivia
    • Botswana
    • Brazil
    • British Indian Ocean Territory
    • Brunei Darussalam
    • Bulgaria
    • Burkina Faso
    • Burundi
    • Cambodia
    • Cameroon
    • Canada
    • Cape Verde
    • Cayman Islands
    • Chad
    • Chile
    • China
    • Christmas Island
    • Cocos (Keeling) Islands
    • Colombia
    • Comoros
    • Cook Islands
    • Costa Rica
    • Croatia
    • Cuba
    • Cyprus
    • Czech Republic
    • Denmark
    • Djibouti
    • Dominica
    • Dominican Republic
    • Ecuador
    • Egypt
    • El Salvador
    • Equatorial Guinea
    • Eritrea
    • Estonia
    • Ethiopia
    • Falkland Islands
    • Faroe Islands
    • Fiji
    • Finland
    • France
    • French Guiana
    • French Polynesia
    • French Southern Territories
    • Gabon
    • Gambia
    • Germany
    • Ghana
    • Gibraltar
    • Greece
    • Greenland
    • Grenada
    • Guadeloupe
    • Guam
    • Guatemala
    • Guinea
    • Guinea-Bissau
    • Guyana
    • Haiti
    • Honduras
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Iraq
    • Ireland
    • Israel
    • Italy
    • Jamaica
    • Japan
    • Jordan
    • Kenya
    • Kiribati
    • Kuwait
    • Laos
    • Latvia
    • Lebanon
    • Lesotho
    • Liberia
    • Libya
    • Liechtenstein
    • Lithuania
    • Luxembourg
    • Macao
    • Madagascar
    • Malawi
    • Malaysia
    • Maldives
    • Mali
    • Malta
    • Marshall Islands
    • Martinique
    • Mauritania
    • Mauritius
    • Mayotte
    • Mexico
    • Monaco
    • Mongolia
    • Montserrat
    • Morocco
    • Mozambique
    • Myanmar
    • Namibia
    • Nauru
    • Nepal
    • Netherlands
    • Netherlands Antilles
    • New Caledonia
    • New Zealand
    • Nicaragua
    • Niger
    • Nigeria
    • Niue
    • Norfolk Island
    • Northern Mariana Islands
    • Norway
    • Oman
    • Pakistan
    • Palau
    • Palestinian Territory
    • Panama
    • Papua New Guinea
    • Paraguay
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Qatar
    • Romania
    • Rwanda
    • Samoa
    • Saudi Arabia
    • Senegal
    • Seychelles
    • Sierra Leone
    • Singapore
    • Slovakia
    • Slovenia
    • Solomon Islands
    • Somalia
    • South Africa
    • Spain
    • Sri Lanka
    • St Kitts and Nevis
    • St Lucia
    • Sudan
    • Suriname
    • Swaziland
    • Sweden
    • Switzerland
    • Taiwan
    • Thailand
    • Togo
    • Tonga
    • Trinidad and Tobago
    • Tunisia
    • Turkey
    • Tuvalu
    • Uganda
    • United Arab Emirates
    • United Kingdom
    • United States
    • Uruguay
    • Vanuatu
    • Venezuela
    • Vietnam
    • Virgin Islands
    • Western Sahara
    • Yemen
    • Zambia
    • Zimbabwe

Chromatography

Pall’s Cadence BioSMB platform is the first disposable flow path, continuous multi-column chromatography solution that is fully scalable from the PD laboratory to GMP manufacturing.
Pall’s Cadence BioSMB platform is the first disposable flow path, continuous multi-column chromatography solution that is fully scalable from the PD laboratory to GMP manufacturing.
Read more

Featured Product: Cadence™ BioSMB Process 80 and 350 Systems

Pall’s Cadence BioSMB platform provides a highly flexible multi-column chromatography system that delivers high throughput and very efficient media utilization when compared to traditional batch, and other continuous chromatography methodologies. This is achieved through a unique single-use eight column system architecture which enables highly flexible flow configuration through the single-use valve cassette. Additionally, the platform is fully scalable from process development (PD) to commercial manufacture. There are two flow range variants available targeted to Perfusion (Cadence BioSMB Process 80 system) and Batch (Cadence BioSMB Process 350 system) bioreactor based processes.  

Clarification

The Cadence Acoustic Separator in conjunction with a polishing depth filter will continuously remove cells and cell debris from cell culture in a closed system, without the need for centrifugation or primary depth filtration.
The Cadence Acoustic Separator in conjunction with a polishing depth filter will continuously remove cells and cell debris from cell culture in a closed system, without the need for centrifugation or primary depth filtration.
Read more

Featured Product: Cadence Acoustic Separator

Cells and particulates from the cell culture are continuously entrained by the standing acoustic wave of the Cadence Acoustic Separator, clarifying the cell culture from the bioreactor. The cell culture fluid passes unimpeded through the system and after a polishing step using a depth filter produces harvested cell culture fluid (HCCF) suitable for purification. 

Inline Concentration

Patented SPTFF (single pass tangential flow filtration) technology enables continuous concentration of the product.
Patented SPTFF (single pass tangential flow filtration) technology enables continuous concentration of the product.
Read more

Featured Product: Cadence Inline Concentrator

The Cadence Inline Concentrator eliminates the requirement for re-circulation typically required for TFF, reducing shear damage and time for the processing step and improving quality of the process.    

Featured Product: Cadence™ Inline Diafiltration Module

Pall’s new Cadence Inline Diafiltration (ILDF) device delivers scalable continuous final ultrafiltration (UF)/DF of drug substance with proven selectivity and low binding attributes.

 

Built with conventional cassettes in Delta regenerated cellulose or Omega™ polyethersulfone membrane, the preconfigured, holder-less modules enable removal factors of ≥ 3-log, with a single pass through the device. 

Featured Product: Cadence™ Virus Inactivation System

The Cadence Virus Inactivation (VI) system is a fully automated system that provides the ability to perform low pH virus inactivation to an incoming elution stream continuously, with minimal operator involvement. The system will collect the elution stream from a Cadence BioSMB Process system, however it can easily process as standalone system or with a batch chromatography system. Automation of the manual operations of elution collection, titration to low pH, hold, titration to high pH and then transfer out. The system comprises of a control unit which attaches to one or two system specific Allegro™ single-use mixers dependent on the application. The specification of the manifolds currently supports 24 hours continuous operation.

Watch Video

Game Changing Advances in Continuous Processing

Ask Biopharmaceuticals A Question

Choose Industry
  • Corporate
  • Aerospace
  • Biopharmaceuticals
  • Chemicals & Polymers
  • Food & Beverage
  • Industrial Manufacturing
  • Laboratory
  • Medical
  • Microelectronics
  • Oil & Gas
  • Power & Utilities
Choose Support Type
  • Customer Service
  • General Inquiry
  • Quality Assurance
  • Tech Support

Thank you for your inquiry.

Your inquiry has been received and will be reviewed by a Pall representative.